TY - JOUR
T1 - Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency
AU - Sefer, Asena Pinar
AU - Abolhassani, Hassan
AU - Ober, Franziska
AU - Kayaoglu, Basak
AU - Bilgic Eltan, Sevgi
AU - Kara, Altan
AU - Erman, Baran
AU - Surucu Yilmaz, Naz
AU - Aydogmus, Cigdem
AU - Aydemir, Sezin
AU - Charbonnier, Louis Marie
AU - Kolukisa, Burcu
AU - Azizi, Gholamreza
AU - Delavari, Samaneh
AU - Momen, Tooba
AU - Aliyeva, Simuzar
AU - Kendir Demirkol, Yasemin
AU - Tekin, Saban
AU - Kiykim, Ayca
AU - Baser, Omer Faruk
AU - Cokugras, Haluk
AU - Gursel, Mayda
AU - Karakoc-Aydiner, Elif
AU - Ozen, Ahmet
AU - Krappmann, Daniel
AU - Chatila, Talal A.
AU - Rezaei, Nima
AU - Baris, Safa
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/4
Y1 - 2022/4
N2 - Purpose: MALT1 deficiency is a combined immune deficiency characterized by recurrent infections, eczema, chronic diarrhea, and failure to thrive. Clinical and immunological characterizations of the disease have not been previously reported in large cohorts. We sought to determine the clinical, immunological, genetic features, and the natural history of MALT-1 deficiency. Methods: The clinical findings and treatment outcomes were evaluated in nine new MALT1-deficient patients. Peripheral lymphocyte subset analyses, cytokine secretion, and proliferation assays were performed. We also analyzed ten previously reported patients to comprehensively evaluate genotype/phenotype correlation. Results: The mean age of patients and disease onset were 33 ± 17 and 1.6 ± 0.7 months, respectively. The main clinical findings of the disease were recurrent infections (100%), skin involvement (100%), failure to thrive (100%), oral lesions (67%), chronic diarrhea (56%), and autoimmunity (44%). Eosinophilia and high IgE were observed in six (67%) and two (22%) patients, respectively. The majority of patients had normal T and NK cells, while eight (89%) exhibited reduced B cells. Immunoglobulin replacement and antibiotics prophylaxis were mostly ineffective in reducing the frequency of infections and other complications. One patient received hematopoietic stem cell transplantation (HSCT) and five patients died as a complication of life-threatening infections. Analyzing this cohort with reported patients revealed overall survival in 58% (11/19), which was higher in patients who underwent HSCT (P = 0.03). Conclusion: This cohort provides the largest analysis for clinical and immunological features of MALT1 deficiency. HSCT should be offered as a curative therapeutic option for all patients at the early stage of life.
AB - Purpose: MALT1 deficiency is a combined immune deficiency characterized by recurrent infections, eczema, chronic diarrhea, and failure to thrive. Clinical and immunological characterizations of the disease have not been previously reported in large cohorts. We sought to determine the clinical, immunological, genetic features, and the natural history of MALT-1 deficiency. Methods: The clinical findings and treatment outcomes were evaluated in nine new MALT1-deficient patients. Peripheral lymphocyte subset analyses, cytokine secretion, and proliferation assays were performed. We also analyzed ten previously reported patients to comprehensively evaluate genotype/phenotype correlation. Results: The mean age of patients and disease onset were 33 ± 17 and 1.6 ± 0.7 months, respectively. The main clinical findings of the disease were recurrent infections (100%), skin involvement (100%), failure to thrive (100%), oral lesions (67%), chronic diarrhea (56%), and autoimmunity (44%). Eosinophilia and high IgE were observed in six (67%) and two (22%) patients, respectively. The majority of patients had normal T and NK cells, while eight (89%) exhibited reduced B cells. Immunoglobulin replacement and antibiotics prophylaxis were mostly ineffective in reducing the frequency of infections and other complications. One patient received hematopoietic stem cell transplantation (HSCT) and five patients died as a complication of life-threatening infections. Analyzing this cohort with reported patients revealed overall survival in 58% (11/19), which was higher in patients who underwent HSCT (P = 0.03). Conclusion: This cohort provides the largest analysis for clinical and immunological features of MALT1 deficiency. HSCT should be offered as a curative therapeutic option for all patients at the early stage of life.
KW - Inborn errors of immunity
KW - MALT1
KW - combined immune deficiency
KW - failure to thrive
KW - hematopoietic stem cell transplantation
KW - immune dysregulation
KW - primary immunodeficiency
KW - recurrent infections
KW - skin involvement
UR - https://www.scopus.com/pages/publications/85123499766
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000784584900080&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1007/s10875-021-01191-4
DO - 10.1007/s10875-021-01191-4
M3 - Article
C2 - 35079916
AN - SCOPUS:85123499766
SN - 0271-9142
VL - 42
SP - 634
EP - 652
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
IS - 3
ER -